There is growing evidence that the TMB can also predict response to ICIs, with the high TMB-patients exhibiting a higher response rate to anti-PD-1/PD-L1 agents possibly due to increased neo-antigen load and T cell infiltration in the tumour microenvironment (14, 15). This evidence concerns the gene CD274 and neoplasm.